Chromoblastomycosis (CBM) is a chronic subcutaneous mycosis caused by traumatic 26 implantation of many species of black fungi. Due to the refractoriness of some cases 27 and common recurrence of CBM, a more effective and less time-consuming treatment is 28 mandatory. The aim of this study was to identify compounds with in vitro antifungal 29 activity in the Pathogen Box® compound collection against different CBM agents. 30 Synergism of these compounds with drugs currently used to treat CBM was also 31 assessed. An initial screening of the drugs present in this collection at 1μM was 32 performed with a Fonsecaea pedrosoi clinical strain according to the EUCAST 33 protocol. The compounds with activity against this fungus were also tested against other 34 seven etiologic agents of CBM (Cladophialophora carrionii, Phialophora verrucosa, 35 Exophiala jeanselmei, Exophiala dermatitidis, Fonsecaea monophora, Fonsecaea 36 nubica, and Rhinocladiella similis) at concentrations ranging from 0.039 to 10 μM. The 37 analysis of potential synergism of these compounds with itraconazole and terbinafine 38 was performed by the checkerboard method. Eight compounds inhibited more than 60% 39 of the F. pedrosoi growth: difenoconazole, bitertanol, iodoquinol, azoxytrobin, 40 MMV688179, MMV021013, trifloxystrobin, and auranofin. Iodoquinol produced the 41 lowest MIC values (1.25 -2.5µM) and MMV688179 showed MICs that were higher 42 than all compounds tested (5 ->10µM). When auranofin and itraconazole were tested in 43 combination, a synergistic interaction (FICI = 0.37) was observed against the C. 44 carrionii isolate. In summary, auranofin, iodoquinol, and MMV021013 were identified 45 as promising compounds to be tested in CBM models of infection. 46 47 Keywords: chromoblastomycosis, new antifungal drugs, Pathogen Box® 51 Chromoblastomycosis (CBM) is a subcutaneous neglected mycosis [1]. It is 52 caused by the implantation of one of its etiological agents through a trauma to the skin. 53 Black fungi from the genera Fonsecaea, Cladophialophora, Rhinocladiella, 54 Phialophora, Exophiala, among others, can cause CBM. Since this mycosis is not of 55 compulsory notification in most countries where it occurs, its distribution is based on 56 case reports and case series, with most of them occurring in Latin America, Africa, and 57 Asia. In South America, most of the cases of CBM have been described in Brazil, in 58 Africa most cases come from Madagascar, and China is the leading Asian country on 59 number of cases [2]. 60 CBM mainly affects agricultural and construction workers, which develop 61 extensive injuries with damage to the affected limb [3]. Most patients often take a long 62 time to seek for medical help, therefore their lesions are usually extensive [2]. Although 63
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Introduction use. Compounds found to have dangerous side-effects were further excluded from the 152 analysis.
153
Synergism evaluation: Synergistic activity between the selected compounds and 154 standard antifungal drugs used in the treatment of CBM (itraconazole and terbinafine) 155 was tested by the checkerboard method [18] . Two drugs were loaded into a single 96-156 well plate, so that in each of the wells there were different concentrations of the 157 compound-antifungal combination. Compound/antifungal dilutions were prepared 158 following the methodology proposed by the EUCAST, starting from a 100-fold 159 concentrated stock compound/antifungal solution according to the MIC determination 160 methodology [16] . Final concentrations of the standard drugs corresponded to 0.06 -4 161 µg/ml (itraconazole) and 0.015 -1 µg/ml (terbinafine). Serial two-fold dilutions of the 162 selected Pathogen Box® compounds were performed so that the MIC of that compound 163 was in a central position of the plate (lines 5-7). Fungal inocula and incubation 164 conditions were the same that were described for the previous experiments. The drug among the compounds that we tested for antifungal activity. Seven out of the eight HepG2 cells; c CC 50 PMM cells; SI: selectivity index = CC 50 (µM) / MIC (µM). The higher is the ratio obtained, the more selective is the compound against the fungal 480 pathogen. 
Figure legends
(difenoconazole); B -MMV688942 (bitertanol); C -MMV688179 (2-[3-chloro-4-[5- 464 [2-chloro-4-(diaminomethylideneamino)phenyl]furan-2-yl]phenyl]guanidine); D - 465 MMV002817 (iodoquinol); E -MMV688754 (trifloxystrobin); F -MMV021013 (N-
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AUR: auranofin; TRB: terbinafine; IOD: iodoquinol; BIT: bitertanol; FICI: fractional inhibitory concentration index.
